FLuc Reporter Cell Line - U-118MG

U-118 MG is a well-established human glioblastoma cell line, originally derived in the late 1960s from a malignant astrocytoma resected from a 50-year-old Caucasian male patient. Growing as an adherent monolayer with mixed morphological characteristics—displaying both astrocytic and multipolar fibroblast-like traits—U-118 MG serves as a foundational model in neuro-oncology for studying the aggressive pathogenesis of glioblastoma multiforme (GBM). The FLuc Reporter Cell Line - U-118MG advances this critical brain tumor model through the stable genetic integration of the firefly luciferase (FLuc) gene into the cellular genome. This targeted engineering allows the cells to constitutively express the luciferase enzyme, producing a highly robust and easily quantifiable bioluminescent signal upon exposure to the standard substrate D-luciferin. Crucially, the genetic modification is strictly designed to preserve the essential biological properties of the parental line. The engineered reporter cells maintain their characteristic morphology, highly invasive growth dynamics, and complex genetic profile—including well-documented mutations in the PTEN and TP53 tumor suppressor genes—providing a biologically authentic and reliable platform for central nervous system (CNS) cancer research.

The functional integration of the firefly luciferase reporter transforms the U-118MG cell line into an indispensable asset for both in vitro analytics and complex preclinical animal modeling. In standard laboratory environments, the continuous bioluminescent output serves as a highly sensitive metric for quantifying cell proliferation, monitoring metabolic viability, and conducting high-throughput screening of novel targeted therapies or standard chemotherapeutics. The primary advantage of this cell line, however, is fully realized in advanced in vivo neuro-oncology studies. Because intracranial tumors cannot be measured using traditional physical methods, orthotopically implanting these FLuc-expressing cells directly into the brains of immunodeficient mice creates highly accurate xenograft models that can be monitored optically. The robust light emission facilitates highly sensitive, non-invasive bioluminescence imaging (BLI) directly through the skull. This advanced capability empowers researchers to visually map early intracranial tumor engraftment, dynamically track aggressive GBM progression, and evaluate whether experimental therapeutics or advanced immunotherapies can successfully penetrate the blood-brain barrier (BBB) to exert anti-tumor effects in living subjects over extended timelines.